Resource Hub
8 Reasons Why Generic AI Systems are Not Suitable for Life Sciences Companies
Unlike some other industries, the risks of using generic AI are much higher in Life Sciences due to stringent regulations and rules around data and information processing. See how you can avoid the common pitfalls of choosing generic AI and what you should require instead Avoid limited Siloed AI Capabilities
CARA AI for Quality, Intelligent Quality Management, Built In
For Quality teams, CARA AI replaces manual firefighting and fragile traceability with predictive oversight, consistent documentation, and audit-ready control, while removing the time and risk created by manual QMS processes. With CARA AI for Quality Predictive oversight instead of firefightingEmerging risks are surfaced early from deviations, complaints, and audits. Dramatically
Replacing Legacy Systems at Scale: Bayer’s Global Migration to the CARA Platform
85,000 Users 900,000 Documents Documentum Replacement A global upgrade involving almost million regulatory documents, streamlined infrastructure, and a strategic move from Documentum to the modern, cloud-based CARA platform. Read the Case Study
Generis Celebrates New Milestone: Egyptian Drug Authority Chooses EXTEDOpulse Powered by CARA
We are proud to congratulate our partner EXTEDO on the signing of a new agreement with Digital Access to Finance (DAF), under the witness of the Chairman of the Egyptian Drug Authority (EDA), Dr. Ali El-Ghamrawy. This agreement marks the launch of Phase II of Egypt’s regulatory digital-transformation programme. As
Bridging the Gap: AI for Life Sciences Without Compromising Compliance
Generic AI tools can’t handle pharma’s reality. They don’t guarantee audit trails. They fragment your validated systems. They create regulatory risks faster than they solve operational problems. But here’s what’s also true: teams that figure out compliant AI deployment will dominate the next decade. CARA AI solves the problem everyone
Global Pharma Modernises Archiving with CARA Platform
13 Terabytes of content across two repositories 65 Million documents and records requiring migration Ongoing archive requests continuing during migration A global pharmaceutical company needed to modernise its document archiving infrastructure to reduce costs, eliminate system redundancy, and meet evolving regulatory requirements. Read the Case Study
Merck: Consolidating 12 Siloed Solutions to a Single Platform with CARA.
85,000 Users 12 Systems Consolidated 18 Million Documents Merck, the oldest pharmaceutical company in the world, implement the CARA Life Sciences Platform to consolidate and unify multiple siloed systems across Quality, Regulatory, Safety, and Clinical (eTMF) processes. Read the Case Study
From Months to Minutes: Can AI Really Transform Regulatory Submissions?
From Months to Minutes: Can AI Really Transform Regulatory Submissions? For regulatory professionals, the idea of cutting hundreds of hours of painstaking work down to just a few clicks has always felt out of reach. Imagine Module 2 and Module 3 documents generated directly from data. Product labels compared across
